Compare Axon Enterprise Inc (AXON) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axon Enterprise Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Axon Enterprise Inc trades at $634.68 (market cap $51.69B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.
| AXON | REGN | |
|---|---|---|
Market Cap | $51.69B | $82.06B |
Sector | Technology | Health |
52-Week High | $791.62 | $812.27 |
52-Week Low | $345.94 | $555.51 |
Enterprise Value | $52.83B | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise (AXON) trades at $571.01, up 9.29% with strong momentum following Q2 2026 results showing 35% revenue growth and 10 consecutive quarters above 30% expansion. Technical indicators show bullish moving averages with current price near resistance at $587. The company maintains dominant positioning in public safety technology with accelerating AI and counter-drone business segments driving future growth potential.
Axon presents compelling growth prospects with raised 2026 revenue guidance of 32-34% and expanding software ecosystem, though elevated valuations (P/E 248) and margin pressures from service mix shifts warrant caution. Analyst consensus remains strongly bullish with $685 price target representing 20% upside potential from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
